Company Overview
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +1,235.62% |
| 6 Months: | +188.46% |
| 3 Months: | +19.56% |
| 1 Month: | +39.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ERAS Erasca, Inc. R2K | 19.50 | -20.97 | $6.06B | 0.00% | -38.33% | -69.86% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -7.28M | -11.16M | -19.61M | -28.18M | -46.04M | -36.51M | -35.91M | -36.96M | -37.02M | -35.97M | -34.66M | -38.85M | -67.78M | -37.24M | -35.63M | -38.12M | -34.55M | -187.91M |
| Net Income | -23.66M | -5.49M | -10.61M | -18.02M | -28.21M | -46.07M | -36.46M | -35.61M | -35.49M | -33.20M | -31.78M | -30.36M | -35.02M | -63.20M | -31.20M | -30.97M | -33.88M | -30.61M | -183.44M |
| Diluted EPS | - | - | - | - | -1.20 | -0.46 | -0.31 | -0.30 | -0.29 | -0.22 | -0.21 | -0.20 | -0.23 | -0.29 | -0.11 | -0.11 | -0.12 | -0.11 | -0.60 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -109.25M | -124.88M | -247.45M | -141.53M | -179.59M | -140.91M |
| Net Income | -101.66M | -122.76M | -242.81M | -125.04M | -161.65M | -124.55M |
| Diluted EPS | - | -1.85 | -1.99 | -0.83 | -0.69 | -0.44 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 124.83M | - | 514.91M | 395.30M | 502.53M | 396.15M |
| Current Assets | - | - | - | 444.50M | 320.68M | 308.79M | 286.24M |
| Cash & Equivalents | - | 65.38M | - | 284.22M | 93.08M | 67.74M | 73.81M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 17.40M | - | 103.06M | 78.61M | 79.03M | 70.98M |
| Current Liabilities | - | 13.68M | - | 48.69M | 26.16M | 31.39M | 28.51M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 55.10M | 55.86M | 51.89M | 47.14M |
| Total Equity | -13.60M | -113.98M | - | 411.85M | 316.69M | 423.50M | 325.17M |
| Shares Outstanding | - | - | - | 149.33M | 151.46M | 283.22M | 284.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.69M | -79.60M | -103.26M | -101.22M | -109.42M | -95.45M |
| Investing Cash Flow | -71.20M | -64.59M | -71.08M | -91.22M | -156.62M | 100.42M |
| Financing Cash Flow | 139.99M | 439.40M | 98.08M | 1.29M | 240.70M | 1.10M |
| Capital Expenditure | -947.00K | -11.21M | -14.55M | -1.77M | -60.00K | -128.00K |
| Free Cash Flow | -33.63M | -90.81M | -117.81M | -102.99M | -109.48M | -95.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 89.2% | - | -59.0% | -39.5% | -38.2% | -38.3% |
| ROCE % | -98.3% | - | -53.1% | -38.3% | -38.1% | -38.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 7.93% | 24.68M | $456.98M |
| 2 | T. Rowe Price Investment Management, Inc. | 6.84% | 21.26M | $393.73M |
| 3 | Blackrock Inc. | 6.48% | 20.15M | $373.20M |
| 4 | Venrock Adviser, LLC | 5.27% | 16.38M | $303.41M |
| 5 | RTW Investments LP | 5.20% | 16.16M | $299.23M |
| 6 | Vivo Capital, LLC | 3.91% | 12.15M | $225.05M |
| 7 | Vanguard Capital Management LLC | 3.62% | 11.25M | $208.35M |
| 8 | Siren, L.L.C. | 3.62% | 11.24M | $208.24M |
| 9 | Logos Global Management LP | 3.59% | 11.15M | $206.50M |
| 10 | Paradigm Biocapital Advisors LP | 3.34% | 10.39M | $192.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ERAS
Why Erasca (ERAS) Stock Is Up Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE1URDRaa2pMb3VVNnpWWVFGMHl5Q1JtODF5bzN4eHd6RWFVZWJFNGQ5aGc1Z1NGellYSEw0bERYU3B5ckFrRndGcDhxa3VLZ1Z5ZF9KaUQxZVh4bEVRay03TGxHTk9MUVhYU1hBMks2MjZ6NUVtdV9aT0l6M28?oc=5" target="_blank">…
Erasca (Nasdaq: ERAS) prices $550.0M upsized public stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOdWZ0a3lNLU05dUd5NndYY0dZOUdMbHlTNm5rN3o3SGVZUW56cHpCdXpOY3dRcm9fSV9HTFdMQW8xN1dyZDAxUmx5VVdJVHRpV0tOcldKS3hTbWlKQkxmUUhWZ04tUWd5djhvbTJ0Ulc1SDZzZ05nV1lfR01zeGhiOGh0LXFPZ1hOeDQtMF…
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQRDdRZktna0ZienNMdzI4ZkFpaFpCZ05HM2NSakZkQWhSWjJDOTFyMmNrUndQRXRjbWV0MnRINEV3NHI5cHlDSmdhd2hOcUVjWlNGcUdYT2Y4cWlUQ0lRcTdnckNrbENKSkhsd2ZIdjVJMDJtT2EtYndyN3lSS3pYMGNzX1RaRnJYMmdOQW…
ERAS Increases Stock Offering to $550 Million - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOYTN6Mnk3ZGt4bXdLUmdES24ySEVsYUM3TXlOV25vd1YwcGw5dXhuUWc3aWY3NTdrY2k2ZTNrbmFuSzkwSFhMT19vaFNpek96OG4yNnR3NndGaXB2bk9aYUdxTW0xMkpGZFlXcHNkVGRHcU42Q3N3MjJUeW85QkZWZllXdHB3SURwTzBz?o…
Erasca prices upsized $550M common stock offering, expects ~$516M net proceeds - TradingView
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNQWJTbV9RdFpWdjVmbjJYUHFmVUFaZHNqN1c1a2RmV2ZieFBNaUdKWGdfV1VzY2JnRFJhZ3d5aE9aN0VVV3ZydU8yb1R0ME13cXl3SkxvRjZDcFFjR3B1UVZDQWo1SGlKcWV0WVAtaUdwMElreWIwVXRmdDZuRVhnUm8taHhILUYyNHkycE…
Why Is Erasca Stock Trading Higher Today? - Erasca (NASDAQ:ERAS) - Benzinga
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxQVHJ6MDVwUUpEb1FqYS1jT04yczdRWWhEcWNSVndEQXlPUlRkZThFei02dnYtRDNBMGpQN3MwWW4wbTRDMzduaDVoa0ZIU3pZQnFkUkY1eXJqcDNqak1UdnJ0WFVRMHZ4eTdNcGxuZE1YS3lzRWZjUGN0TlFFNk80QWM2OEp0dXllS0pMbk…
ERAS — Frequently Asked Questions
What is the current share price of Erasca, Inc. (ERAS)?
As of 2026-07-14 21:23 PDT, Erasca, Inc. (ERAS) trades at $19.50 on NasdaqGS. Its 52-week range is $1.39 to $22.47.
What is the market capitalisation of ERAS?
Erasca, Inc. (ERAS) has a market capitalisation of $6.06B on NasdaqGS.
What is the P/E ratio of ERAS?
ERAS trades at a trailing price-to-earnings (P/E) ratio of -20.97. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 11.10.
What is the return on equity (ROE) of ERAS?
ERAS has a return on equity (ROE) of -69.86%. Its return on capital employed (ROCE) is -38.33%.
Is ERAS a good stock to buy?
This page provides a data-driven analysis of Erasca, Inc. (ERAS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.